H2020HORIZONFP7
Asphalion SL
- Country
- ESSpain
- Defence projects
- 0
- Projects, all programmes
- 22
- As coordinator
- 0
- EU contribution (CORDIS)
- EUR 4,938,159
- Active
- 2013 to 2025
Projects
22 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| MEDiCSAnticancer approach based on the Metabolic Disruption of Cancer Stem Cells with high effectivity across a wide range of solid tumours | HORIZON | 2025 | Participant | EUR 152,813 |
| VIVIDClinical Validation of In Vivo Imaging for Detecting Immune Dynamics | HORIZON | 2025 | Participant | EUR 127,500 |
| KeratOPrinterAdvanced 4D Printing Technologies in Corneal Regeneration: A Pathway to Restored Vision | HORIZON | 2025 | Participant | EUR 266,875 |
| HYDROHEALMulti-functional hydrogels for promoting bone fracture healing through local induced release of pharmaceutical agents and gradual matrix replacement by the regenerating bone | HORIZON | 2025 | Participant | EUR 195,563 |
| PragmaTILPragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors | HORIZON | 2023 | Participant | EUR 168,125 |
| NABIHEALANTIMICROBIAL NANOSTRUCTURED BIOMATERIALS FOR COMPLEX WOUND HEALING | HORIZON | 2023 | Participant | EUR 133,750 |
| IMMUTOLADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED DISEASES | HORIZON | 2023 | Participant | EUR 197,500 |
| SINPAINA game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis | HORIZON | 2022 | Participant | EUR 204,375 |
| ETERNALBoosting the reduction of the environmental impact of pharmaceutical products throughout their entire life cycle. | HORIZON | 2022 | Participant | EUR 151,500 |
| RBDCOVRBD Dimer recombinant protein vaccine against SARSCoV2 | HORIZON | 2021 | Participant | EUR 350,000 |
| IN2SIGHTAN IN VIVO BIOENGINEERED CHIP AS A SMART INTRAVITAL MULTIPHOTON IMAGING WINDOW FOR NEW VALIDATION PROTOCOLS OF BIOMATERIALS | H2020 | 2021 | Participant | EUR 265,000 |
| Tumor-LN-oCTumor and Lymph Node on Chip for cancer studies | H2020 | 2021 | Participant | EUR 236,875 |
| SPIOMET4HEALTHPCOS IN ADOLESCENT GIRLS AND YOUNG WOMEN: TOWARD A TREATMENT GUIDED BY PATHOPHYSIOLOGY | H2020 | 2021 | Participant | EUR 223,125 |
| MISTRALMicrobiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination | H2020 | 2020 | Participant | EUR 316,188 |
| SBRSMART BONE REGENERATION | H2020 | 2020 | Participant | EUR 318,125 |
| VASCOVIDPORTABLE PLATFORM FOR THE ASSESSMENT OF MICROVASCULAR HEALTH IN COVID-19 PATIENTS AT THE INTENSIVE CARE | H2020 | 2020 | Participant | EUR 182,179 |
| CardioReGenixCardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease | H2020 | 2019 | Participant | EUR 310,035 |
| HIVACAREvaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection | H2020 | 2017 | Participant | EUR 175,000 |
| nTRACKMultimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration | H2020 | 2017 | Participant | EUR 305,733 |
| MYOCUREDevelopment of an innovative gene therapy platform to cure rare hereditary muscle disorders | H2020 | 2016 | Participant | EUR 275,000 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.